Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

Original reporting
Published Nov 18, 2026, 10:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up — source image
Decision brief

The 30-second read

$RXRXBullishMed
01

Why it matters

By agreeing on a composite event-free survival primary endpoint that counts clinically meaningful adenoma removals plus other events, the FDA alignment reduces trial-design risk and clarifies what constitutes success for registrational evaluation.

02

Market read

Traders can reassess REC-4881’s regulatory de-risking and timeline, but the next major inflection (Phase 3 start and later readout) is still in the future.

03

What to watch

The dosing schedule depends on ongoing TUPELO trial results, so uncertainty remains around the final regimen and how it translates to the Phase 3 endpoint.

Relevance 7/10Novelty 7/10Timing: today’s FDA alignment news, with Phase 3 start expected in 2H 2027

Background

REC-4881 is an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP), a condition with no approved pharmacologic therapies and ongoing surveillance needs after colectomy.

Company-level read

Ticker impact

$RXRXBullishHigh confidence
Context

Recursion says it aligned with the FDA on REC-4881 Phase 3 registrational trial design, including a composite event-free survival endpoint.

Expected impact

Likely upward bias as traders price reduced regulatory uncertainty and a clearer path to a future registrational trial start.

Evidence & confidence

The article discloses a specific FDA alignment on primary endpoint construction and trial framework, plus an expected Phase 3 start window in 2H 2027.

Market effects

Reinforces investor focus on MEK-pathway oncology and GI polyp prevention programs with FDA-agreed endpoints.

Limited direct regional spillover; primarily affects US small/mid-cap biotech sentiment.

Modest global relevance as FAP is rare and the catalyst is FDA-specific trial design.

Counterpoint

Endpoint alignment does not guarantee efficacy; traders may still discount the Phase 3 probability given the long timeline to 2H 2027 initiation.

Key entities

  • Recursion Pharmaceuticals, Inc.

    Sponsor of REC-4881 and the party reaching FDA alignment on Phase 3 trial design.

  • REC-4881

    Investigational oral MEK1/2 inhibitor being evaluated in FAP.

  • U.S. Food and Drug Administration (FDA)

    Aligned on the registrational Phase 3 trial design and primary endpoint definition.

Related articles

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.

$RXRXMedAI 8/10

Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline

Recursion Pharmaceuticals (RXRX) reported Q3 2026 net loss narrowed to $119.0M from $162.3M YoY. Revenue rose to $18.55M, driven by a $10M Sanofi milestone payment. REC-4881 showed positive FAP trial results, with significant polyp burden reductions. REC-1245 demonstrated preliminary efficacy in cancers. RXRX expects cash to last into 2029. Stock is down 4.96% to $3.83.